Margy Meislin

New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus 

|

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the investigational litifilimab in development by Biogen significantly reduced skin disease activity in cutaneous lupus erythematosus (CLE). These data were presented at the American Academy of Dermatology Annual Meeting on … New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus 

New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

|

A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease activity and lowered steroid use in people with systemic lupus erythematosus (SLE), the most common form of lupus. The results were also presented today at the 15th European Lupus Society meeting, SLEuro 2026.  More than 75% of people treated with Gazyva plus standard therapy achieved at least … New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

Lupus Therapeutics, the Clinical Affiliate of the Lupus Research Alliance, Broadens Proven Peer-to-Peer Program in Clinical Trials

|

Today, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, announced the expansion of its proven peer-to-peer clinical research education program – Patient Advocates for Lupus Studies (PALS) – making it available to hundreds of individuals living with lupus across North America. The expansion builds on the program’s success to date and aims to … Lupus Therapeutics, the Clinical Affiliate of the Lupus Research Alliance, Broadens Proven Peer-to-Peer Program in Clinical Trials

Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

|

New York, N.Y., October 21, 2025 —  With lupus research accelerating at an unprecedented pace, the Lupus Research Alliance heads to ACR Convergence 2025 (October 24-29, Chicago), the annual meeting of the American College of Rheumatology, to demonstrate how its unique impact across the full research continuum is shaping the next generation of treatments and research.  As the … Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis

|

The Lupus Research Alliance applauds the approval by the U.S. Food and Drug Administration of Gazyva® (obinutuzumab) from Genentech for the treatment of adults with active lupus nephritis in combination with standard of care. This is a major step forward for the entire lupus community, as it is the only anti-CD20 monoclonal antibody targeting an … Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis

FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

|
Breaking news: Gazyva for Lupus Nephritis

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. The acceptance is based on results from the Phase 3 REGENCY study showing improved complete renal … FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®

Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study

|
Breaking News

Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at the World Congress of Nephrology reported that results of the Phase III REGENCY trial found that among people with active lupus nephritis, Gazyva® (obinutuzumab) plus standard therapy demonstrated statistically significant and clinically meaningful improvement in the … Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study